Calls Now Open
2026 Scholar-Innovator, Harrington Prize and ADDF-Harrington
The Harrington Project, established in 2012, pioneered a unique non-profit/for-profit model, which included the launch of Harrington Discovery Institute. The model integrates drug development expertise, financial resources, and industry collaborations to accelerate the translation of groundbreaking discoveries into viable medicines. We partner with non-profit organizations, pharmaceutical companies and investors to strategically de-risk, advance, and grow our portfolio of discoveries.
Advent Life Sciences and Harrington have partnered to launch the Advent-Harrington Impact Fund, a global investment fund to advance breakthrough discoveries into novel treatments.
The ADDF-Harrington Scholar Award drives research efforts that seek to prevent, treat or cure Alzheimer's disease, related dementias and cognitive-decline associated with aging.
The Harrington Prize for Innovation in Medicine, awarded jointly with the American Society for Clinical Investigation, honors a physician-scientist globally for an achievement notable for innovation, creativity and potential for clinical application.
BioMotiv is a mission driven investment fund to translate transformative discoveries into novel medicines through alignment with the right investors and commercialization partners.
The Gund Harrington Scholar Award supports the translation of innovative research in retinal degenerative diseases into new therapies to improve and/or restore vision.
Genomics England works with the National Health Services (NHS) to bring forward the use of genomic healthcare and research in Britain to help people live longer, healthier lives.
Morgan Stanley GIFT (Global Impact Funding Trust) Cures powered by Harrington Discovery Institute is a special interest program for philanthropists to amplify their impact by accelerating cures for diseases.
Oxford University Hospitals (OUH) is a world-renowned center of clinical excellence and one of the largest NHS teaching trusts in the UK.
Oxford Science Enterprises (OSE) is an independent, billion-pound investment company, created in 2015 to found, fund and build transformational businesses via its unique partnership with the University of Oxford, the world’s #1 research university. OSE has partnered with University Hospitals in Cleveland, Ohio, and the University of Oxford to establish the Therapeutics Accelerator at the Oxford-Harrington Rare Disease Centre.
Oxford University Innovation (OUI) is a wholly-owned subsidiary of the University of Oxford that manages the University's technology transfer and consulting activities.
The Harrington Rare Disease Scholar Award, sponsored by Takeda Pharmaceuticals, supports researchers whose discoveries show promise for translation into novel medicines for rare diseases.
The University of Oxford is a world-leading center of learning, teaching and research and the oldest university in the English-speaking world.